Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial
Top Cited Papers
- 1 February 2014
- journal article
- research article
- Published by Elsevier in The Lancet
- Vol. 383 (9916), 515-523
- https://doi.org/10.1016/s0140-6736(13)62121-2
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Eligibility and Safety of Triple Therapy for Hepatitis C: Lessons Learned from the First Experience in a Real World SettingPLOS ONE, 2013
- 1422 POTENT VIRAL SUPPRESSION WITH ALL-ORAL COMBINATION OF DACLATASVIR (NS5A INHIBITOR) AND GS-7977 (NS5B INHIBITOR), +/− RIBAVIRIN, IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HCV GT1, 2, OR 3Journal of Hepatology, 2012
- 1172 ANTIVIRAL ACTIVITY AND RESISTANCE PROFILE OF THE NOVEL HCV NS5A INHIBITOR GS-5885Journal of Hepatology, 2012
- Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1New England Journal of Medicine, 2012
- Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b–infected null respondersHepatology, 2011
- Telaprevir for Retreatment of HCV InfectionNew England Journal of Medicine, 2011
- Boceprevir for Untreated Chronic HCV Genotype 1 InfectionNew England Journal of Medicine, 2011
- Boceprevir for Previously Treated Chronic HCV Genotype 1 InfectionNew England Journal of Medicine, 2011
- Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis CNature Reviews Gastroenterology & Hepatology, 2011
- Treatment of Chronic Non-A, Non-B Hepatitis with Recombinant Human Alpha InterferonNew England Journal of Medicine, 1986